Dr. Jeff Matous from the Colorado Blood Cancer Institute discusses the use of teclistamab, a bispecific antibody, for treating relapsed myeloma, highlighting his participation in the pivotal MAJESTEC-1 trial.
Link to ASH playlist: [ Ссылка ]
ASH Abstract: Higher Teclistamab Step-up Dosing in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Results from the Majestec-1 Trial
#ASH24 #myeloma #mmsm
Follow HealthTree:
[ Ссылка ]
twitter.com/healthtreeformm
facebook.com/healthtreeformultiplemyeloma
instragram.com/healthtreeformultiplemyeloma
![Гелертер верят - Развитая цивилизация существовала до появления людей? [Времени не существует]](https://s2.save4k.org/pic/pMxzC99_ZkE/mqdefault.jpg)
